Navigation Links
Astellas Adds Two Key Senior Executives at Agensys, Inc.
Date:12/1/2011

SANTA MONICA, Calif., Dec. 1, 2011 /PRNewswire/ -- Agensys, Inc. ("Agensys"), a subsidiary of Astellas (Tokyo:4503,"Astellas") has announced that Frank P. Hudson has been appointed vice president of finance, while Wolfgang Noe, Ph.D., has been named vice president of process sciences and manufacturing.

"Frank and Wolfgang each bring a wealth of experience from the biopharma industry to their respective positions," said Sef Kurstjens, M.D., Ph.D., president and chief executive officer of Agensys. "Frank's experience in research and development finance is exactly what we were looking for in our candidates, and Wolfgang's record in preclinical and clinical drug development brings additional strength to our operations. We are looking forward to their contributions at Agensys."

Astellas acquired Agensys in 2007. Based in Santa Monica, Calif., Agensys is the company's center of antibody product discovery and development operations. A state-of-the-art research and development facility is scheduled for completion in 2013.

Agensys has a rich pipeline that includes four monoclonal antibody products in clinical trials: (1) AGS-1C4D4, directed to Prostate Stem Cell Antigen (PSCA), a target for prostate, pancreatic, and bladder cancers; (2) ASG-5ME, Agensys' first antibody-drug conjugate (ADC), directed to AGS-5, a target in multiple epithelial tumors; (3) AGS-16M8F, an ADC developed for the treatment of metastatic renal cancer; and (4) AGS-22M6E, an ADC developed for multiple solid tumors to include breast, bladder, lung, and pancreatic cancers. Agensys' preclinical pipeline encompasses over 10 different monoclonal antibodies (MAbs) programs. Both ASG-5ME and AGS-22M6E are co-developed with Seattle Genetics.

Hudson joins Agensys from the Mannkind Corporation where he served as vice president of finance since 2007. During a career in the pharmaceutical industry spanning more than 20 years, Hudson headed fiscal management for research and development operations from genetics research through clinical development whose total annual spending exceeded $1.5 billion.  He also has extensive experience within commercial operations and business development.  Hudson holds an MBA from the Fuqua School of Business at Duke University and is a certified public accountant and certified internal auditor. At Agensys, Hudson will be responsible for finance, procurement and information technology.

Noe holds a doctorate in biochemistry from Eberhard-Karl University in Tubingen, Germany. He joins Agensys from Biogen-Idec, where he most recently served as vice president of strategic development and technical alliances. He began his career with Boehringer-Ingelheim Pharmaceuticals in Germany and continued with Biogen-Idec as vice president of bioprocess development for seven years and then vice president of strategic alliances and technical development. As vice president of manufacturing and process sciences at Agensys, Noe will be responsible for manufacturing development and manufacturing of clinical and preclinical drug supplies.

About Agensys
Agensys, Inc., an affiliate of Astellas Pharma Inc., is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers. The MAb product pipeline is generated by Agensys' diverse portfolio of proprietary, clinically relevant cancer targets that encompass 14 types of solid tumors. Agensys' target portfolio and related products are protected by a large patent estate. The company has full capabilities to generate, develop and manufacture antibody products. Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies, directed at a variety of cancer indications, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast and skin. ADC products are based on drug platform technologies developed by Seattle Genetics. Agensys is developing a growing pipeline of clinical stage functional MAbs and ADC products.

About Astellas
Agensys is a subsidiary of Astellas Pharma Inc., located in Tokyo, Japan, a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,800 employees worldwide. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.  

 


'/>"/>
SOURCE Astellas
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)...  Las Vegas ophthalmology practice, Center For Sight, announced ... Dublin ), an implant that shunts ... intraocular pressure in patients with moderate to severe glaucoma. ... glaucoma that can lead to progressive optic nerve damage ... untreated. According to the National Eye Institute, ...
(Date:3/28/2017)... 2017 The U.S. Food and Drug ... adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is ... adequately by topical therapies, or those for whom ... used with or without topical corticosteroids. ... approving new and innovative therapies for patients with ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer Generics ... the various indicators and trend analysis related to ... in mainstream pharmaceutical market in US. The report ... the growth on cancer generics drugs in recent ... saving of billions of dollars for various stake ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, ... the launch of a free, public-facing tool for analyzing the costs of various ... to provide comparative information to patients, providers, insurers and pharmaceutical companies about the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
(Date:3/28/2017)... ... 28, 2017 , ... Usually, the impending arrival of warmer weather means the ... about a double chin, this means more anxiety than elation. The cosmetic dermatology experts ... people, a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
Breaking Medicine News(10 mins):